StockNews.com cut shares of Royalty Pharma (NASDAQ:RPRX – Get Rating) from a buy rating to a hold rating in a research note published on Thursday morning. RPRX has been the subject of several other reports. UBS Group dropped their price target on Royalty Pharma from $51.00 to $48.00 and set a buy rating for the […]
Horizon Kinetics Asset Management LLC reduced its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX – Get Rating) by 2.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 399,880 shares of the biopharmaceutical company’s stock after selling 8,666 shares during the period. Horizon […]
Hikari Tsushin Inc. boosted its holdings in Royalty Pharma plc (NASDAQ:RPRX – Get Rating) by 469.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,220 shares of the biopharmaceutical company’s stock after buying an additional 1,830 shares during the quarter. Hikari Tsushin Inc.’s […]
Formidable Asset Management LLC grew its stake in Royalty Pharma plc (NASDAQ:RPRX – Get Rating) by 16.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 24,721 shares of the biopharmaceutical company’s stock after acquiring an additional 3,431 shares during […]
Edge Capital Group LLC lifted its stake in shares of Royalty Pharma plc (NASDAQ:RPRX – Get Rating) by 15.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,819 shares of the biopharmaceutical company’s stock after acquiring an additional 2,721 […]